IDEA Pharma Mike Rea CEO https://ideapharma.com
Post# of 30067
(Total Views: 763)
Posted On: 05/12/2019 11:52:56 AM
IDEA Pharma
Mike Rea
CEO
https://ideapharma.com/about
Coeptis Pharma
MIKE REA
CHIEF COMMERCIAL OFFICER
Currently CEO of IDEA Pharma, a strategic commercial partner for Coeptis.
PAULA TRZEPACZ, MD
CHIEF MEDICAL OFFICER
http://coeptispharma.com/executive-team/
Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries
JANUARY 11, 2019
The virtual Chief Commercial Officer partnership will provide multi-year commercial strategy to the Amarantus portfolio of companies, with royalties paid to IDEA following successful monetisation. The Amarantus/ IDEA Pharma partnership will run for 5 years, and be renewable upon mutual consent.
Amarantus Provides 2019 Roadmap
JANUARY 07, 2019
Elto Pharma
In December 2018, Amarantus entered into definitive agreements with Coeptis Pharmaceuticals ("Coeptis"
to sell Elto Pharma for 7.5 million shares of Coeptis, with an additional 7.5 million shares being delivered to Elto Pharma shareholders upon the completion of certain milestones. Prior to the acquisition of Elto Pharma, Coeptis has 15 million shares outstanding. Elto Pharma is a joint venture of which Amarantus owns approximately 50%. Elto Pharma's single asset, eltoprazine, received an independent third-party valuation of $316M for its Parkinson's disease levodopa-induced dyskinesia indication (PD-LID) in 2018. Given the nature of our recapitalization, we believe that Amarantus shareholders will benefit the most by allowing certain milestones to be achieved for eltoprazine's full value to be realized by Coeptis. Dual benefits to Amarantus shareholders should accrue from its' participation as a shareholder in the eltoprazine opportunity, as well as in Coeptis' entire product pipeline. Coeptis recently completed a transaction to gain rights to an FDA-approved drug it expects to launch later in 2019, thereby potentially providing cash flow to support eltoprazine's further development, as well as possibly mitigating Amarantus-owned equity dilution in Coeptis down the road.
https://www.amarantus.com/news/press-releases...19-roadmap
KITOV SIGNS MARKETING AND DISTRIBUTION AGREEMENT FOR ITS LEAD PRODUCT CONSENSI™ IN THE U.S. WITH COEPTIS PHARMACEUTICALS
January 3, 2019
KITOV SIGNS MARKETING AND DISTRIBUTION AGREEMENT FOR ITS LEAD PRODUCT CONSENSI™ IN THE U.S. WITH COEPTIS PHARMACEUTICALS
By Coeptis Pharmaceuticals January 3, 2019
– Kitov to receive $3.5M milestone payments and 40% – 60% of net profit on sales of Consensi ™
– Coeptis to cover all CMC, sales, and marketing expenses
TEL AVIV, Israel, Jan. 03, 2019
(GLOBE NEWSWIRE) — Kitov Pharma (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today announced it has signed an exclusive marketing and distribution agreement with Coeptis Pharmaceuticals for the U.S. market. Coeptis will commercialize Kitov’s combination drug, Consensi™, intended to simultaneously treat osteoarthritis pain and hypertension.
The agreement provides for total milestone payments from Coeptis to Kitov of $3.5 million, of which Kitov has already received the initial milestone upon execution of the agreement, and additional milestone payments are due upon completion of an agreed Chemistry, Manufacturing, Contol (CMC) plan and upon first commercial sales in the U.S. In addition, Kitov will be paid 40%-60% of Coeptis’ net profit on Consensi™ sales. The agreement is for a term of fifteen years and may be extended for additional two-year terms and includes customary provisions, as well as certain residual rights and obligations of the parties following termination.
http://coeptispharma.com/kitov-signs-marketin...ceuticals/
Aloha
Mike Rea
CEO
https://ideapharma.com/about
Coeptis Pharma
MIKE REA
CHIEF COMMERCIAL OFFICER
Currently CEO of IDEA Pharma, a strategic commercial partner for Coeptis.
PAULA TRZEPACZ, MD
CHIEF MEDICAL OFFICER
http://coeptispharma.com/executive-team/
Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries
JANUARY 11, 2019
The virtual Chief Commercial Officer partnership will provide multi-year commercial strategy to the Amarantus portfolio of companies, with royalties paid to IDEA following successful monetisation. The Amarantus/ IDEA Pharma partnership will run for 5 years, and be renewable upon mutual consent.
Amarantus Provides 2019 Roadmap
JANUARY 07, 2019
Elto Pharma
In December 2018, Amarantus entered into definitive agreements with Coeptis Pharmaceuticals ("Coeptis"
to sell Elto Pharma for 7.5 million shares of Coeptis, with an additional 7.5 million shares being delivered to Elto Pharma shareholders upon the completion of certain milestones. Prior to the acquisition of Elto Pharma, Coeptis has 15 million shares outstanding. Elto Pharma is a joint venture of which Amarantus owns approximately 50%. Elto Pharma's single asset, eltoprazine, received an independent third-party valuation of $316M for its Parkinson's disease levodopa-induced dyskinesia indication (PD-LID) in 2018. Given the nature of our recapitalization, we believe that Amarantus shareholders will benefit the most by allowing certain milestones to be achieved for eltoprazine's full value to be realized by Coeptis. Dual benefits to Amarantus shareholders should accrue from its' participation as a shareholder in the eltoprazine opportunity, as well as in Coeptis' entire product pipeline. Coeptis recently completed a transaction to gain rights to an FDA-approved drug it expects to launch later in 2019, thereby potentially providing cash flow to support eltoprazine's further development, as well as possibly mitigating Amarantus-owned equity dilution in Coeptis down the road. https://www.amarantus.com/news/press-releases...19-roadmap
KITOV SIGNS MARKETING AND DISTRIBUTION AGREEMENT FOR ITS LEAD PRODUCT CONSENSI™ IN THE U.S. WITH COEPTIS PHARMACEUTICALS
January 3, 2019
KITOV SIGNS MARKETING AND DISTRIBUTION AGREEMENT FOR ITS LEAD PRODUCT CONSENSI™ IN THE U.S. WITH COEPTIS PHARMACEUTICALS
By Coeptis Pharmaceuticals January 3, 2019
– Kitov to receive $3.5M milestone payments and 40% – 60% of net profit on sales of Consensi ™
– Coeptis to cover all CMC, sales, and marketing expenses
TEL AVIV, Israel, Jan. 03, 2019
(GLOBE NEWSWIRE) — Kitov Pharma (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today announced it has signed an exclusive marketing and distribution agreement with Coeptis Pharmaceuticals for the U.S. market. Coeptis will commercialize Kitov’s combination drug, Consensi™, intended to simultaneously treat osteoarthritis pain and hypertension.
The agreement provides for total milestone payments from Coeptis to Kitov of $3.5 million, of which Kitov has already received the initial milestone upon execution of the agreement, and additional milestone payments are due upon completion of an agreed Chemistry, Manufacturing, Contol (CMC) plan and upon first commercial sales in the U.S. In addition, Kitov will be paid 40%-60% of Coeptis’ net profit on Consensi™ sales. The agreement is for a term of fifteen years and may be extended for additional two-year terms and includes customary provisions, as well as certain residual rights and obligations of the parties following termination.
http://coeptispharma.com/kitov-signs-marketin...ceuticals/
Aloha
(2)
(0)